Semaglutide, a third-generation GLP-1 agonist, was initially developed for diabetes management but has shown significant weight loss effects as a secondary benefit. The discovery of its appetite-suppressing properties led to its classification as an anorectic. Newer drugs like terzepatide, which acts on two gut hormones, are even more effective for weight loss, highlighting the evolving landscape of obesity treatment.
